Episode Summary
Dr. Lucy McBride sits down with Dr. Amy Comander, Harvard breast oncologist and author of Paving Your Path Through Breast Cancer and Beyond, to cut through the fear and misinformation around breast cancer. They cover who is at risk, what the screening guidelines mean in practice, what lifestyle factors move the needle, and how to make sense of the HRT and breast cancer conversation.
Risk: Genetics, Bad Luck, and Everything In Between
Only 5–10% of breast cancers in the U.S. are due to identifiable inherited gene mutations—BRCA1 and BRCA2 account for roughly half of those
Another 10–15% involve familial patterns without a single identifiable gene; the remaining majority are sporadic, meaning they occur without an inherited cause we can currently explain
Having breast cancer in your family doesn’t mean you have a genetic mutation—given that one in eight women will develop breast cancer in her lifetime, sometimes it just means you have women in your family
A strong pattern—grandmother, mother, and sister all with breast cancer—is a signal worth discussing with a doctor; a single relative is not necessarily a reason for genetic testing
Screening: Mammograms, Dense Breasts, and MRI
Annual screening with mammography starting at 40 is recommended for average-risk women, with the end point determined by a shared conversation with a doctor
Dense breast tissue makes mammograms harder to read—finding a tumor in extremely dense tissue is like finding a snowman in a snowstorm; about 10% of women have extremely dense tissue and most should add an annual breast MRI staggered six months from their mammogram
Heterogeneously dense tissue is common—up to 40% of women under 50—but not everyone with it needs an MRI; the decision depends on other risk factors and should incorporate a validated risk model like the Tyrer-Cuzick calculator
Breast MRI catches more cancers but also generates more false positives; the downstream anxiety and biopsies are costs that belong in the conversation about pros and cons of MRI as a screening modality
Lifestyle and Prevention
Alcohol is the most consistent and modifiable lifestyle risk factor for breast cancer—even one drink per day carries a small but real increased risk, and the relationship is dose-dependent
Maintaining a healthy weight and engaging in regular physical activity reduce risk, partly by reducing circulating estrogen in post-menopausal women and by improving metabolic health overall
Soy is not a risk factor for breast cancer—this is a persistent myth; soy foods are a good source of plant-based protein and the evidence is clear that they are safe
Risk factors divide into fixed (age, sex, genetics) and modifiable (alcohol, weight, exercise, metabolic health); the goal is to lean into what can be changed without catastrophizing what cannot
HRT and Breast Cancer: Separating Fear from Evidence
The fear around HRT and breast cancer stems largely from the 2002 Women’s Health Initiative study, which used synthetic progestins—not the bioidentical hormones most commonly prescribed today
In the WHI, women who took estrogen alone—those who had undergone hysterectomy—actually had a reduced risk of breast cancer, a finding that was not widely reported
The overall increased risk from combined hormone therapy is small, and causation has not been established; a family history of breast cancer is not an automatic disqualification from HRT
HRT is a tool in the toolkit, not a solution for everyone—the right answer depends on individual risk factors, symptom burden, and what risks a woman is willing to tolerate on both sides of the decision
Vaginal Estrogen and Breast Cancer Survivors
Vaginal estrogen is considered safe for virtually all women, including most breast cancer survivors, because systemic absorption is minimal
It is distinct from systemic HRT and should not be lumped in with it—women who have had breast cancer and are suffering from genitourinary symptoms should know this option exists
For women on systemic HRT who also use vaginal estrogen, the two can be used together; the patch is not a substitute for vaginal estrogen because the tissue itself needs local treatment
Oncologists are increasingly getting educated on menopause management—the divide between oncology and women’s health is closing, and patients benefit when their cancer doctor and primary care doctor are working from the same playbook
Survivorship: Thriving Beyond a Diagnosis
Too many women feel defined by their diagnosis, or guilty that they somehow caused it—neither is warranted, and neither serves the goal of getting better
Breast cancer is not one disease; genomic tools like the Oncotype DX and ProSigna help determine whether chemotherapy is even necessary, sparing many women from treatment that won’t help them
The pillars of thriving after breast cancer mirror the pillars of health generally—sleep, movement, stress management, social connection, and a sense of purpose
Patients have more agency than they often believe: where genetics and diagnosis are fixed, how a woman shows up for her body, her relationships, and her care is not
Upshot
One in eight women will develop breast cancer in their lifetime. Most cases are not due to an inherited genetic mutation. Screening saves lives. HRT is not the villain it was made out to be. And breast cancer patients have more agency than they often think.
If you enjoyed this episode, check out my other conversations on women’s health:
Hormone Therapy, Hot Flashes & Sexual Health with Dr. Lauren Streicher
Menopause, HRT, & Genitourinary health with Dr. Rachel Rubin
My book, Beyond the Prescription, comes out on August 11! I wrote it with you in mind.
